重大事件
即時報告
8-K
2026-06-23
Fortress Biotech 8-K公告2026年股東會投票結果 董事選舉與核數師任命均獲通過
AI 繁中摘要
Fortress Biotech 提交 8-K 申報，報告 2026 年股東週年大會投票結果 📊
生物科技公司 Fortress Biotech（納斯達克代碼：FBIO、FBIOP）於 2026 年 6 月 17 日以網上虛擬形式舉行年度股東大會，並於 6 月 23 日向 SEC 提交 8-K 表格，披露兩項議案的表決結果：
**提案一：選舉七名董事（任期至 2027 年大會）**
所有候選人均獲通過，但部分董事得票差距較大：
- Lindsay A. Rosenwald, M.D.：11,022,326 票贊成，239,772 票反對，32,188 票棄權，另有 12,897,124 票為經紀人非投票（broker non-votes）。
- J. Jay Lobell 獲得最多反對票：1,313,658 票反對，贊成票僅 9,756,949 票。
- Michael S. Weiss 獲最高贊成票：10,961,271 票。
- 其餘董事（Jimmie Harvey Jr.、Malcolm Hoenlein、Dov Klein、Kevin L. Lorenz）贊成票均超過 1,000 萬票。
**提案二：批准聘用 KPMG LLP 為 2026 年度獨立核數師**
- 贊成：23,095,864 票
- 反對：753,612 票
- 棄權：341,934 票
提案順利通過。
本次投票結果反映股東對現有管理層及核數師的整體支持，但部分董事面對較多反對聲音，或需關注股東對特定議題的訴求。對投資者而言，議案通過意味公司治理維持穩定，但經紀人非投票比例高（約 1,290 萬股），顯示部分機構投資者或未就董事選舉表達意向，可能影響未來代理投票策略。
展開英文正文
Fortress Biotech, Inc._June 17, 2026 0001429260false0001429260us-gaap:CommonStockMember2026-06-172026-06-170001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2026-06-172026-06-1700014292602026-06-172026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2026 Fortress Biotech, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35366 (Commission File Number) 20-5157386 (IRS Employer Identification No.) 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (Address of Principal Executive Offices) (781) 652-4500 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act. ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act. ☐Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock FBIO Nasdaq Capital Market 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders. On June 17, 2026, Fortress Biotech, Inc. (the “Company” or “Fortress”) held its annual meeting of stockholders (the “2026 Annual Meeting”) at 10:00 a.m. Eastern Time by means of an online virtual meeting platform. At the 2026 Annual Meeting, the following two proposals were voted on by the stockholders: (i) the election of seven directors to hold office until the 2027 annual meeting of stockholders or until such director resigns or is removed from office; and (ii) the ratification of the appointment of KPMG LLP as Fortress’s independent registered public accounting firm for the year ending December 31, 2026. The proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting filed with the Securities and Exchange Commission on April 28, 2026. Proposal 1 The votes with respect to the election of seven directors to hold office until the 2027 annual meeting of stockholders were as follows: Total Votes Broker Non- Director Total Votes For Against Abstentions Votes Lindsay A. Rosenwald, M.D. 11,022,326 239,772 32,188 12,897,124 Jimmie Harvey, Jr., M.D. 10,322,230 923,184 48,872 12,897,124 Malcolm Hoenlein 10,309,261 932,328 52,697 12,897,124 Dov Klein, CPA 10,323,030 931,434 39,822 12,897,124 J. Jay Lobell 9,756,949 1,313,658 223,679 12,897,124 Kevin L. Lorenz, J.D. 10,131,410 939,137 223,739 12,897,124 Michael S. Weiss 10,961,271 270,249 62,766 12,897,124 Proposal 2 The vote with respect to the ratification of the selection of KPMG LLP as Fortress’s independent registered accounting firm for the year ending December 31, 2026 was as follows: Total Votes For Total Votes Against Abstentions 23,095,864 753,612 341,934 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) Date: June 23, 2026 By: /s/ David Jin David Jin Chief Financial Officer